Clinical Trial Update: Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial exploring whether SGLT2 inhibitors reduce peritoneal glucose uptake in patients undergoing peritoneal dialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Peritoneal Dialysis Complication

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: Holbaek Sygehus | Conditions: End Stage Renal Disease, Peritoneal Dialysis Complication | Phase 2 | Status: UNKNOWN